ArticleAdvances in therapy2020

Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China.

Lifeng Mu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.